Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$2.58 - $6.13 $88,236 - $209,646
-34,200 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$18.76 - $40.91 $33,130 - $72,247
1,766 Added 5.44%
34,200 $764,000
Q4 2020

Feb 16, 2021

BUY
$27.6 - $48.03 $895,178 - $1.56 Million
32,434 New
32,434 $1.56 Million

About Sigilon Therapeutics, Inc.


  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.